Similar articles

• Azithromycin Susceptibility Among Neisseria gonorrhoeae Isolates and Seasonal Macrolide Use.

  Olesen SW, Torrone EA, Papp JR, Kirkcaldy RD, Lipsitch M, Grad YH. Olesen SW, et al. J Infect Dis. 2019 Jan 29;219(4):619-623. doi: 10.1093/infdis/jiy551. J Infect Dis. 2019. PMID: 30239814 Free PMC article.
• Further evidence to support the individualised treatment of gonorrhoea with ciprofloxacin.

  Trembizki E, Guy R, Donovan B, Kaldor JM, Lahra MM, Whiley DM; GRAND study investigators. Trembizki E, et al. Lancet Infect Dis. 2016 Sep;16(9):1005-1006. doi: 10.1016/S1473-3099(16)30271-7. Lancet Infect Dis. 2016. PMID: 27684341 No abstract available.
• Future treatment of gonorrhea--novel emerging drugs are essential and in progress?

  Unemo M, Shafer WM. Unemo M, et al. Expert Opin Emerg Drugs. 2015 Sep;20(3):357-60. doi: 10.1517/14728214.2015.1039981. Epub 2015 Jul 3. Expert Opin Emerg Drugs. 2015. PMID: 25907334 Free PMC article. No abstract available.
• Drug-resistant Neisseria gonorrhoeae: latest developments.

  Suay-García B, Pérez-Gracia MT. Suay-García B, et al. Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1065-1071. doi: 10.1007/s10096-017-2931-x. Epub 2017 Feb 16. Eur J Clin Microbiol Infect Dis. 2017. PMID: 28210887 Review.
• New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance.

  Lewis DA. Lewis DA. Sex Health. 2019 Sep;16(5):449-456. doi: 10.1071/SH19034. Sex Health. 2019. PMID: 31292063 Review.